Edition:
United Kingdom

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

305.55DKK
23 May 2018
Change (% chg)

kr.-2.75 (-0.89%)
Prev Close
kr.308.30
Open
kr.306.65
Day's High
kr.307.00
Day's Low
kr.302.70
Volume
2,327,882
Avg. Vol
3,067,706
52-wk High
kr.354.80
52-wk Low
kr.260.20

Select another date:

Fri, May 4 2018

BRIEF-Novo Nordisk Says Initiated New Share Repurchase Programme For Up To Dkk 2.7 Billion

* AS PART OF UPTO DKK 14 BILLION 2018 SHARE REPURCHASE PROGRAMME, CO INITIATED NEW SHARE REPURCHASE PROGRAMME FOR AN AMOUNT OF UP TO DKK 2.7 BILLION

BRIEF-Novo Nordisk A/S purchases B Shares worth Dkk 1,038 Mln from Novo Holdings A/S under 2018 share repurchase programme

* NOVO NORDISK A/S PURCHASES B SHARES WORTH DKK 1,038 MILLION FROM NOVO HOLDINGS A/S UNDER THE 2018 SHARE REPURCHASE PROGRAMME

Novo Nordisk upbeat on new diabetes drug as profit tops forecast

COPENHAGEN Novo Nordisk , the world's biggest maker of diabetes drugs, reported a smaller than expected fall in first-quarter profit and nudged up its full-year forecast as sales of new medicines helped to soften the hit from a weaker U.S. dollar.

Drugmaker Novo Nordisk beats first quarter profit expectations, nudges up 2018 outlook

COPENHAGEN Denmark's Novo Nordisk , the world's biggest maker of diabetes drugs, reported first-quarter operating profit above expectations on Wednesday and raised the lower end of its 2018 sales and profit forecast.

UPDATE 2-Novo Nordisk upbeat on new diabetes drug as profit tops forecast

* U.S. legislation puts pressure on 2019 sales (Adds CEO quotes, share price)

BRIEF-Novo Nordisk CEO: New Ozempic Drug To Reach At Least DKK 1 Billion Sales In 2018

May 2 NOVO NORDISK A/S CEO LARS FRUERGAARD JORGENSEN SAID AT CALL AFTER Q1 EARNINGS:

Drugmaker Novo Nordisk beats Q1 profit expectations, nudges up 2018 outlook

COPENHAGEN, May 2 Denmark's Novo Nordisk , the world's biggest maker of diabetes drugs, posted a posted first-quarter operating profit above expectations on Wednesday and lifted the lower end of its 2018 sales and profit outlook.

BRIEF-Novo Nordisk Beats Q1 Expectations; Lifts 2018 Guidance A Tad

* OPERATING PROFIT DECREASED BY 8% IN DANISH KRONER AND INCREASED BY 6% IN LOCAL CURRENCIES IN THE FIRST THREE MONTHS OF 2018

BRIEF-Novo Nordisk Investigates Hypoglycaemia's Impact On Diabetes

* PARTICIPATES IN NEW RESEARCH PROJECT HYPO-RESOLVE TO INVESTIGATE HYPOGLYCAEMIA AND ITS IMPACT IN DIABETES

BRIEF-Emisphere Technologies Amended Its Existing 2015 Development And License Agreement With Novo Nordisk

* EMISPHERE TECHNOLOGIES INC - AMENDED ITS EXISTING 2015 DEVELOPMENT AND LICENSE AGREEMENT WITH NOVO NORDISK A/S

Select another date: